PHARMACOLOGICAL AND PHARMACOECONOMIC ASSESSMENTS ON THERAPEUTIC EQUIVALENCE OF ANTI-HCV DRUGS

The new challenge for this decade is to understand which strategy should be implemented to continue the HCV elimination plan in Italy, considering separate factors: on the one hand the further expansion of patient recruitment criteria by AIFA (to date 12) and on the other the conclusion of the three-year period of innovative status with the consequent exit from the innovative drugs fund.

INDICE:
– Abstract
– Pharmacological dissertation
– Comparison based on the therapeutic equivalence criteria indicated by AIFA
– Economic dissertation
– Conclusions
– Biblioghraphy